Ted Love hopes to use his experience across drug development to improve the industry's reputation following a bruising lobbying fight.June 5, 2023Check out STAT+Sponsored By Courtesy of Global Blood Therapeutics STAT+ | Ted Love, BIO's first Black board chair, aims to rehab biotech's image in Washington Ted Love hopes to use his experience across drug development to improve the biotech industry's reputation following a bruising lobbying fight By Rachel Cohrs STAT+ | How Blue Cross Blue Shield insurers ratcheted up profits in 2022 Blue Cross Blue Shield insurers' 2022 profits underscore how much financial and political power they still hold in their respective states. By Bob Herman STAT+ | FDA oncology head wants advisory panels to keep voting on new drugs Richard Pazdur begs to differ with his boss, the commissioner, on the importance of recording the opinions of independent experts on approval. By Angus Chen Adobe 'We arguably saved their lives': Newborn DNA-sequencing reveals elevated cancer risks for parents Three mothers who learned they carried a gene that drastically elevated their cancer risks chose to undergo prophylactic surgeries. By Megan Molteni STAT+ | Carbon Health is already using AI to write patient records Primary care tech startup Carbon is using AI to listen to patient appointments and automatically write up near-complete notes within minutes. By Mohana Ravindranath Akero's NASH drug combined with Ozempic cut liver fat in small study In a small study, patients taking Akero's NASH drug with a GLP-1 like Ozempic had reduced liver fat and improved markers of liver scarring. By Elaine Chen Listen: For Long Island mothers, community efforts address 'an injustice made purposefully invisible' On Long Island, the white infant mortality rate is 2 deaths per 1,000 live births. For Black babies, it's 8 to 9 deaths per 1,000 live births. By Nicholas St. Fleur STAT+ | Bellerophon Therapeutics trial fails despite innovative digital endpoint Bellerophon is abandoning a Phase 3 trial of its pulmonary fibrosis treatment after patients using a digital endpoint showed no improvement. By Mario Aguilar More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments